Retrospective Longitudinal Study of Gestational Weight Gain Among Chinese Pregnant Women (GWGCPW)

May 11, 2017 updated by: Jing Tan, West China Hospital
The purpose of this study is to investigate the reference ranges and rates of gestational weight gain among Chinese pregnant women, and to analyze the correlation between gestational weight gain and adverse outcomes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10422

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Chinese pregnant women who had deliveries at West China Women and Children's Hospital, Sichuan University

Description

Inclusion Criteria:

  1. Deliveries between January 2013 and December 2014;
  2. Gestational age between 37 weeks or older and less than 42 weeks;
  3. Registration with care documents at the first prenatal visit prior to the 15th gestational week;
  4. Had at least five follow-up visits until delivery.

Exclusion Criteria: None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Preeclampsia
Time Frame: After 20th gestational weeks till delivery, about 5 months
Maternal systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg during gestation. Urine protein ≥5.0 g within 24h, urine volume <400 mL. HELLP syndrome or pulmonary edema present.
After 20th gestational weeks till delivery, about 5 months
Eclampsia
Time Frame: After 20th gestational weeks till delivery, about 5 months
Tonic-clonic seizures (convulsions) in preeclampsia patients, including convulsions and coma, not due to pre-existing or organic brain disorders.
After 20th gestational weeks till delivery, about 5 months
ICP
Time Frame: After 14th gestational weeks till delivery, about 6 months
Intrahepatic cholestasis of pregnancy.
After 14th gestational weeks till delivery, about 6 months
Placenta previa
Time Frame: During pregnancy till delivery
Placenta partially or entirely covered the lower uterine segment diagnosed using antenatal ultrasound.
During pregnancy till delivery
Gestational diabetes
Time Frame: After 24th gestational weeks, about 4 months
By oral glucose tolerance test between 24th and 28th gestational weeks (fasting glucose ≥5.1 mmol/L, 1-h glucose ≥10.0 mmol/L, 2-h glucose ≥8.5 mmol/L; one abnormal result sufficient).
After 24th gestational weeks, about 4 months
Ruptured uterus
Time Frame: During delivery
Rupture of maternal uterus confirmed by laparotomy.
During delivery
Placental abruption
Time Frame: After 20th gestational weeks till delivery, about 5 months
Abruption of a normally positioned placenta before delivery, diagnosed by clinical symptoms, ultrasound, fetal heart monitoring, or laboratory tests.
After 20th gestational weeks till delivery, about 5 months
Postpartum hemorrhage
Time Frame: Within 24h after delivery
Postpartum bleeding volume ≥500 mL.
Within 24h after delivery
Hepatic diseases
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Hepatitis-B/C/E virus infection, acute fatty liver disease, or severe hepatitis.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Hematological diseases
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Iron-deficiency anemia, thalassemia, hemophilia, idiopathic thrombocytopenic purpura, aplastic anemia, or disseminated intravascular coagulation.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Gynecological diseases
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Uterine fibroids, ovarian cyst, cervical carcinoma, pelvic inflammation, or ovarian carcinoma.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Respiratory diseases
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Pneumonia, bronchitis, asthma or pulmonary tuberculosis.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Thyroid disease
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Hyperthyroidism or hypothyroidism.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
ICU admission
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Admission to intensive care unit.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Maternal death
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Maternal death.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Macrosomia
Time Frame: within 1 month after delivery
Birth weight >4000 g.
within 1 month after delivery
Infant of low-birth weight
Time Frame: within 1 month after delivery
Birth weight <2500 g.
within 1 month after delivery
Neonatal ICU admission
Time Frame: Within 1 month after delivery
Admission to neonatal intensive care unit.
Within 1 month after delivery
Neonatal death
Time Frame: Within 1 month after delivery
Neonatal death.
Within 1 month after delivery
Large for gestational age
Time Frame: Within 1 month after delivery
Neonatal weight, length, or head circumference above the 90th percentile for that gestational age.
Within 1 month after delivery
Small for gestational age
Time Frame: Within 1 month after delivery
Neonatal weight, length, or head circumference below the 10th percentile for that gestational age.
Within 1 month after delivery
Neonatal defect
Time Frame: Within 1 month after delivery
Neonatal defect.
Within 1 month after delivery
Maternal adverse outcomes
Time Frame: During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
There occurred one or more of preeclampsia, eclampsia, ICP, placenta previa, gestational diabetes, ruptured uterus, placental abruption, postpartum hemorrhage, hepatic diseases, hematological diseases, gynecological diseases, respiratory diseases, thyroid disease, ICU admission, or maternal death.
During pregnancy, delivery or within 42 days of pregnancy termination, an average of 1 year
Neonatal adverse outcomes
Time Frame: Within 1 month after delivery
There occurred one or more of macrosomia, low-birth weight, neonatal ICU admission, neonatal death, large for gestational age, small for gestational age, or neonatal defect.
Within 1 month after delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
West China Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
West China Second University Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Xin Sun, Doctor, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 24, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 11, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 16, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 16, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 11, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GWG-China-2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gestational Weight Gain

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings